Mao Yuqing, Zhang Shaoren, Yu Fujun, Li Huanqing, Guo Chuanyong, Fan Xiaoming
Department of Gastroenterology and Hepatology, Jinshan Hospital of Fudan University, Shanghai 201508, China.
Department of Gastroenterology and Hepatology, Shanghai Tenth People's Hospital of Tongji University, Shanghai 200072, China.
Int J Mol Sci. 2015 Sep 10;16(9):21911-30. doi: 10.3390/ijms160921911.
Ghrelin is a stomach-derived growth hormone secretagogue that promotes various physiological effects, including energy metabolism and amelioration of inflammation. The purpose of this study was to investigate the protective mechanism of ghrelin against liver fibrosis. Liver fibrosis was induced in C57BL/6 mice by intraperitoneal injection of CCl₄ (2.0 mL/kg of 10% CCl₄ v/v solution in peanut oil) two times per week for eight weeks. Ghrelin (10 μg/kg) was intraperitoneally injected two times per week for eight weeks. A second murine liver fibrosis model was induced by bile duct ligation (BDL) and concurrent ghrelin administration for four weeks. Hematoxylin eosin (H&E), and Masson's trichrome were used to detect pathological changes to liver tissue. Western blotting was used to detect protein levels of transforming growth factor (TGF)-β1, phosphorylated Smad3 (p-Smad3), I-collage, α-smooth muscle actin (α-SMA), matrix metalloproteinases (MMPs) 2, tissue inhibitor of matrix metalloproteinases (TIMPs) 1, phosphorylated NF-κB (p-NF-κB), and microtubule-associated protein light chain 3 (LC3). In addition, qRT-PCR was used to detect mRNA levels of TGF-β1, I-collage, α-SMA, MMP2, TIMP1 and LC3, while levels of TGF-β1, p-Smad3, I-collage, α-SMA, and LC3 were detected immunohistochemically. Levels of aspartate aminotransferase and alanine aminotransferase were significantly decreased by ghrelin treatment. Ghrelin administration also significantly reduced the extent of pathological changes in both murine liver fibrosis models. Expression levels of I-collage and α-SMA in both models were clearly reduced by ghrelin administration. Furthermore, ghrelin treatment decreased protein expression of TGF-β1 and p-Smad3. The protein levels of NF-κB and LC3 were increased in the CCl₄- and BDL-treatment groups but were significantly reduced following ghrelin treatment. In addition, ghrelin inhibited extracellular matrix formation by decreasing NF-κB expression and maintaining the balance between MMP2 and TIMP1. Our results demonstrated that ghrelin attenuates liver fibrosis via inhibition of the TGF-β1/Smad3 and NF-κB signaling pathways, as well as autophagy suppression.
胃饥饿素是一种由胃产生的生长激素促分泌素,可促进多种生理效应,包括能量代谢和炎症改善。本研究的目的是探讨胃饥饿素对肝纤维化的保护机制。通过每周两次腹腔注射四氯化碳(2.0 mL/kg,10%四氯化碳体积分数的花生油溶液),连续八周,诱导C57BL/6小鼠发生肝纤维化。胃饥饿素(10 μg/kg)每周腹腔注射两次,共八周。通过胆管结扎(BDL)诱导建立第二种小鼠肝纤维化模型,并同时给予胃饥饿素四周。采用苏木精-伊红(H&E)染色和Masson三色染色检测肝组织的病理变化。采用蛋白质印迹法检测转化生长因子(TGF)-β1、磷酸化Smad3(p-Smad3)、I型胶原、α-平滑肌肌动蛋白(α-SMA)、基质金属蛋白酶(MMPs)2、基质金属蛋白酶组织抑制剂(TIMPs)1、磷酸化核因子κB(p-NF-κB)和微管相关蛋白轻链3(LC3)的蛋白水平。此外,采用qRT-PCR检测TGF-β1、I型胶原、α-SMA、MMP2、TIMP1和LC3的mRNA水平,同时采用免疫组织化学法检测TGF-β1、p-Smad3、I型胶原、α-SMA和LC3的水平。胃饥饿素治疗可显著降低天冬氨酸转氨酶和丙氨酸转氨酶水平。给予胃饥饿素还可显著减轻两种小鼠肝纤维化模型的病理变化程度。胃饥饿素给药可明显降低两种模型中I型胶原和α-SMA的表达水平。此外,胃饥饿素治疗可降低TGF-β1和p-Smad3的蛋白表达。在四氯化碳和BDL治疗组中,NF-κB和LC3的蛋白水平升高,但在胃饥饿素治疗后显著降低。此外,胃饥饿素通过降低NF-κB表达并维持MMP2和TIMP1之间的平衡来抑制细胞外基质形成。我们的结果表明,胃饥饿素通过抑制TGF-β1/Smad3和NF-κB信号通路以及自噬抑制来减轻肝纤维化。